medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2021, Number 4

<< Back Next >>

Rev Mex Patol Clin Med Lab 2021; 68 (4)

Oxidative stress biomarkers in chronic kidney disease

Gallardo JM, Flores-Maldonado CE, González-Márquez H, Guerra-Araiza CH, Paniagua R

Language: Spanish
References: 61
Page: 188-194
PDF size: 262.39 Kb.


ABSTRACT

Kidney disease represents a serious global health problem. Its late diagnosis is one of the main concerns since it is only feasible in an advanced disease stage. The lack of clinical manifestations in the early stages of the disease and the fact that the variables usually determined in kidney function are only notably reduced in the advanced stages is the leading cause of late detection. Biochemical and molecular changes in diseased kidney tissue occur before plasma nitrogenous substances, such as creatinine and urea, begin to accumulate. Biomarkers are substances that are used as an indicator of a biological state; They must be able to be objectively measured and evaluated as an indicator of a normal biological process, pathogenic state, or response to medical treatment. Free radicals (FR) and pro-oxidants produced during acute or chronic kidney injury can further aggravate the disease's course and play a role in the pathogenesis of subsequent complications. The free oxygen radicals that mitochondria produce increase the kidneys' susceptibility to induced damage when oxidative stress occurs.


REFERENCES

  1. Manns B, Hemmelgarn B, Tonelli M, Au F, So H, Weaver R et al. The cost of care for people with chronic kidney disease. Can J Kidney Health Dis. 2019; 6: 2054358119835521.

  2. Honeycutt AA, Segel JE, Zhuo X, Hoerger TJ, Imai K, Williams D. Medical costs of CKD in the medicare population. J Am Soc Nephrol. 2013; 24 (9): 1478-1483.

  3. Collister D, Pannu N, Ye F, James M, Hemmelgarn B, Chui B et al. Health care costs associated with AKI. Clin J Am Soc Nephrol. 2017; 12 (11): 1733-1743.

  4. Takemoto Y, Naganuma T. Economic issues of chronic kidney disease and end-stage renal disease. Contrib Nephrol. 2019; 198: 87-93.

  5. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017; 13 (4): 241-257.

  6. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager K, Tonelli M et al. Chronic kidney disease. Nat Rev Dis Primers. 2017; 3 (1): 17088.

  7. Wouters OJ, O'Donoghue DJ, Ritchie J, Kanavos PG, Narva AS. Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol. 2015; 11 (8): 491-502.

  8. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997; 82 (2): 291-295.

  9. Eirin A, Lerman A, Lerman LO. The emerging role of mitochondrial targeting in kidney disease. Handb Exp Pharmacol, 2017; 240: 229-250.

  10. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003; 18 (7): 1272-1280.

  11. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014; 371 (1): 58-66.

  12. Baumgaertel MW, Kraemer M, Berlit P. Neurologic complications of acute and chronic renal disease. Handb Clin Neurol. 2014; 119: 383-393.

  13. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39 (1): 44-84.

  14. Colak E. New markers of oxidative damage to macromolecules. J Med Biochem. 2008; 27 (1): 1-16.

  15. Harman D. The aging process. PNAS. 1981; 78 (11): 7124-7128.

  16. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn Rev. 2010; 4 (8): 118-126.

  17. Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001; 30 (11): 1191-1212.

  18. Sies H. 1-oxidative stress: introductory remarks. In: Sies H (ed.). Oxidative stress. London: Academic Press; 1985. pp. 1-8.

  19. Grootveld M, Halliwell B. Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo? Biochem J. 1987; 243 (3): 803-808.

  20. Otero P, Viana M, Herrera E, Bonet B. Antioxidant and prooxidant effects of ascorbic acid, dehydroascorbic acid and flavonoids on LDL submitted to different degrees of oxidation. Free Radic Res. 1997; 27 (6): 619-626.

  21. Pearson P, Lewis SA, Britton J, Young IS, Fogarty A. The pro-oxidant activity of high-dose vitamin E supplements in vivo. BioDrugs. 2006; 20 (5): 271-273.

  22. Holley AE, Cheeseman KH. Measuring free radical reactions in vivo. Br Med Bull. 1993; 49 (3): 494-505.

  23. Palmieri B, Sblendorio V. Oxidative stress tests: overview on reliability and use. Part I. Eur Rev Med Pharmacol Sci. 2007; 11 (5): 309-342.

  24. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res. 2004; 43 (3): 200-227.

  25. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014; 2014: 360438.

  26. Davies MJ. Protein oxidation and peroxidation. Biochem J. 2016; 473 (Pt 7): 805-825.

  27. Münch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem. 1997; 35 (9): 669-677.

  28. Henderson PT, Evans MD, Cooke MS. Salvage of oxidized guanine derivatives in the (2'-deoxy) ribonucleotide pool as source of mutations in DNA. Mutat Res. 2010; 703 (1): 11-17.

  29. Broedbaek K, Siersma V, Henriksen T, Weimann A, Petersen M, Andersen JT et al. Urinary markers of nucleic acid oxidation and cancer in type 2 diabetes. Redox Biol. 2015; 4: 34-39.

  30. Palmieri B, Sblendorio V. Oxidative stress tests: overview on reliability and use. Part II. Eur Rev Med Pharmacol Sci. 2007; 11 (6): 383-399.

  31. Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic. Nephrol Ther. 2016; 12 (Suppl 1): S41-S48.

  32. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80 (12): 1258-1270.

  33. Aveles PR, Criminácio CR, Goncalves S, Bignelli AT, Claro LM, Siqueira SS et al. Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Prac. 2010; 116 (4): c294-c299.

  34. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A et al. Oxidative stress is progressively enhanced with advancing stages of CKD. AJKD, 2006; 48 (5): 752-760.

  35. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M et al. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011; 34 (1): 12-19.

  36. Duni A, Liakopoulos V, Roumeliotis S, Peschos D, Dounousi E. Oxidative stress in the pathogenesis and evolution of chronic kidney disease: untangling Ariadne's thread. Int J Mol Sci. 2019; 20 (15): 3711.

  37. Kao MP, Ang DS, Pall A, Struthers AD. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J Hum Hypertens. 2010; 24 (1): 1-8.

  38. Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 2017; 92 (5): 1051-1057.

  39. Granata S, Zaza G, Simone S, Villani G, Latorre D, Pontrelli P et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics. 2009; 10 (1): 388.

  40. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54 (6): 1615-1625.

  41. Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metabolism. 2012; 15 (2): 186-200.

  42. Dieter BP, Alicic RS, Meek RL, Anderberg RJ, Cooney SK, Tuttle KR. Novel therapies for diabetic kidney disease: storied past and forward paths. Diabetes Spectr. 2015; 28 (3): 167-174.

  43. Galvan DL, Badal SS, Long J, Chang BH, Schumacker PT, Overbeek PA et al. Real-time in vivo mitochondrial redox assessment confirms enhanced mitochondrial reactive oxygen species in diabetic nephropathy. Kidney Int. 2017; 92 (5): 1282-1287.

  44. Landray MJ, Wheeler DC, Lip GYH, Newman DJ, Blann AD, McGlynn FJ et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. AJKD. 2004; 43 (2): 244-253.

  45. Goicoechea M, García de Vinuesa S, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17 (12 Suppl 3): S231-S235.

  46. Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. Nephrol Ther. 2006; 2 (3): 111-119.

  47. Kisic B, Miric D, Dragojevic I, Rasic J, Popovic L. Role of myeloperoxidase in patients with chronic kidney disease. Oxid. 2016; 2016: 1069743.

  48. Greiber S, Muller B, Daemisch P, Pavenstadt H. Reactive oxygen species alter gene expression in podocytes: induction of granulocyte macrophage - colony - stimulating factor. J Am Soc Nephrol. 2002; 13 (1): 86-95.

  49. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440 (7081): 237-241.

  50. Sakamaki I, Inai K, Tsutani Y, Ueda T, Tsutani H. Binding of monosodium urate crystals with idiotype protein efficiently promote dendritic cells to induce cytotoxic T cells. Cancer Sci. 2008; 99 (11): 2268-2273.

  51. Amaya Y, Yamazaki K, Sato M, Noda K, Nishino T, Nishino T. Proteolytic conversion of xanthine dehydrogenase from the NAD-dependent type to the O2-dependent type. Amino acid sequence of rat liver xanthine dehydrogenase and identification of the cleavages of the enzyme protein during irreversible conversion by trypsin. J Biol Chem. 1990; 265 (24): 14170-14175.

  52. Nishino T, Okamoto K, Kawaguchi Y, Hori H, Matsumura T, Eger BT et al. Mechanism of the conversion of xanthine dehydrogenase to xanthine oxidase: identification of the two cysteine disulfide bonds and crystal structure of a non-convertible rat liver xanthine dehydrogenase mutant. J Biol Chem. 2005; 280 (26): 24888-24894.

  53. Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med. 1994; 16 (3): 339-346.

  54. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase - catalyzed 3 - chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 2001; 31 (10): 1163-1169.

  55. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995; 41 (8): 1135-1138.

  56. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006; 5: 4.

  57. Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol. 2005; 18 (6): 721-726.

  58. Shang W, Huang L, Li L, Li X, Zeng R, Ge S et al. Cancer risk in patients receiving renal replacement therapy: a meta-analysis of cohort studies. Mol Clin Oncol. 2016; 5 (3): 315-325.

  59. Capeillere-Blandin C, Delaveau T, Descamps-Latscha B. Structural modifications of human beta 2 microglobulin treated with oxygen-derived radicals. Biochem J. 1991; 277 (1): 175-182.

  60. Mathis KW, Venegas-Pont M, Masterson CW, Stewart NJ, Wasson KL, Ryan MJ. Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus. Hypertension. 2012; 59 (3): 673-679.

  61. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004; 24 (5): 469-473.




2020     |     www.medigraphic.com